The global point of care (PoC) diagnostics market is anticipated to reach USD 20.9 billion by 2024, according to a new report by Grand View Research, Inc. Rise in the R&D funding and research activities amongst the market players in order to introduce novel POC tests and devices for ease of disease detection and monitoring is expected to fuel industrial progress through to 2024.
Moreover, the introduction of favorable regulatory initiatives in order to promote the development and adoption of POC diagnostic tests is anticipated to propel growth in the coming years. Furthermore, advancement of diagnostic laboratories and adaptation of more integrated and automated lab systems are also factors expected to fuel demand for advanced workflow systems and drive the digital pathology and workflow segment through to 2024.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry
Further key findings from the report suggest:
·
Glucose testing accounted for the largest share
in revenue in 2015 owing to the higher prevalence of diabetes. Presence of
significant product portfolio pertaining to glucose testing in the market and
the presence of a number of major players as wells as local manufacturers from
different regions are factors attributive to contribute substantially to the
revenue generated.
·
Hb1Ac POC tests are more reliable for glucose
testing and due to the vast patient base for diabetes management, this segment
is second in terms of revenue generation in the POC market only to its
counterpart. Owing to the presence of glucose testing segment as a potential
market and growing cost effectiveness of Hb1Ac tests, it is expected that over
the coming decade it will witness considerable growth in demand and usage
·
POC tests for infectious disease testing, is
another segment of prime activity in the point of care industry. This segment
includes rapid diagnostic tests for a considerable number of diseases including
HIV, HBV, RSV, HPV, Influenza, HCV, MRSA, TB/dr-TB & HSV among others.
·
Owing to the growing incidence of a number of
infectious diseases, initiatives taken by a number of governments to implement
early diagnosis and screening, and development of rapid tests able to
distinguish between a wide number of pathogens this segment has been observed
to be at the demand receiving end in the industry for the better half of the
last decade and is only expected to witness growth in demand.
·
Hospitals are estimated to be the dominant
end-users for POC diagnosis industry owing to higher penetration of products
and comparatively higher usage rate for disease monitoring and diagnosis.
·
North America dominated the market in 2015, with
over 43% of total revenue. Presence of major entities with widespread
distribution network coupled with significant number of research endeavors
carried out in the U.S is supportive for the largest share of region. Moreover,
point of care diagnostics is a relatively more advanced segment of in vitro
diagnostics and owing to the presence of high R&D expenditure,
availability of a technologically advanced healthcare infrastructure along with
the presence of a number of ongoing government funded research projects are
factors accounting for the region’s large share.
·
Asia Pacific is projected to witness lucrative
growth in the coming years owing to the developments carried out in developing
economies herein in order to develop the healthcare infrastructure and reduce
the incidence of target diseases.
·
Major participants of this market include Roche,
Abbott Laboratories, Siemens Healthcare, Danaher Corporation, BioMerieux,
Johnson & Johnson, Abaxis Inc., Alere Inc., Qiagen N.V., Spectral Diagnostics,
Instrumentation Laboratory, Nova Biomedical, Nipro Diagnostics, Trinity
Biotech, and Sekisui.
·
Participants are involved in adopting
competitive strategies in order to enhance the market presence. These companies
are also involved in collaborations with hospitals in order to maintain the
market share.
·
For instance, in April 2015, Nipro diagnostics
participated in an industry event named AMCP (Academy of Managed Care Pharmacy)
in support of providing care to the patients with diabetes.
Read detailed report or request for sample of this research report: - http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry/request
Grand View Research has segmented point of care diagnostics market on the basis of application, end-use, and region:
Global Point of Care Diagnostics Outlook, by Product (Revenue, USD Million, 2013 - 2024)
·
Glucose Testing
·
Hb1Ac Testing
·
Infectious Disease Testing
·
HIV POC
·
Clostridium difficile POC
·
HBV POC
·
Pneumonia or Streptococcus associated infections
·
Respiratory syncytial virus (RSV) POC
·
HPV POC
·
Influenza/Flu POC
·
HCV POC
·
MRSA POC
·
TB and drug-resistant TB POC
·
HSV POC
·
Other Infectious Diseases
·
Coagulation
·
Fertility
·
Cardiac markers
·
Primary care systems
·
Hematology
·
Decentralized Clinical Chemistry
·
Feces
·
Blood Gas/Electrolytes
·
Ambulatory Chemistry
·
Urinalysis
·
Drug Abuse Testing
Global Point of Care Diagnostics Outlook, by End-use (Revenue, USD Million,
2013 - 2024)
·
Clinics
·
Hospitals
·
Assisted Living Healthcare Facilities
·
Laboratory
·
Others
Point of Care Diagnostics Regional Outlook (Revenue, USD Million,
2013 - 2024)
·
North America
·
U.S.
·
Canada
·
Europe
·
Germany
·
UK
·
Spain
·
France
·
Italy
·
Asia Pacific
·
China
·
Japan
·
India
·
Singapore
·
Korea
·
Australia
·
Latin America
·
Brazil
·
Mexico
·
Argentina
·
Chile
·
MEA
·
South Africa
·
Nigeria
·
Kenya
·
UAE
·
Saudi Arabia
·
Qatar
·
Zimbabwe
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/clinical-diagnostics
No comments:
Post a Comment